Description of the blood test:

Beta-2 Microglobulin (B2M) is a small protein found on the surface of nearly all nucleated cells in the body. It is part of the MHC class I molecule, which plays a key role in the immune system. Because B2M is constantly “shed” into the blood as cells turn over, its levels reflect cell turnover and immune activity. In the kidneys, B2M is filtered by the glomeruli but then almost completely reabsorbed by the tubules. This makes it a unique tool for checking both the “filtering” and “reabsorbing” functions of the kidneys.

What Does the Test Represent?

• Goal: To measure the concentration of B2M in the blood or urine.
• Main Application:
  • In Blood: As a prognostic marker for Multiple Myeloma, Lymphoma, and Chronic Lymphocytic Leukemia (CLL).
  • In Urine: To distinguish between damage to the kidney’s filters (glomeruli) and its tubes (tubules).
• Method: Immunoassay (ELISA or Immunoturbidimetry).

Collection Recommendations (General)

• Timing: Morning collection is standard.
• Fasting: Fasting for 8–12 hours is recommended.
• Material: Venous blood (serum) or a 24-hour/spot urine sample.
• Specific Rules: If testing urine, it is vital to keep the sample at a stable pH, as B2M is unstable in highly acidic urine. Your doctor may provide a preservative for the container.

Factors Influencing the Result

• Inflammation: Since B2M is linked to the immune system, any infection, inflammation, or autoimmune flare can cause a temporary rise in blood levels.
• Kidney Filtration: If the kidneys are not filtering blood properly (low GFR), B2M will build up in the blood regardless of whether a tumor is present.
• Viral Infections: High levels are often seen in patients with HIV or Cytomegalovirus (CMV), reflecting chronic immune activation.

When to Take This Test?

• Recommendations: If you have been diagnosed with Multiple Myeloma (to determine the stage and prognosis); if you have signs of kidney transplant rejection; or if you have been exposed to heavy metals like cadmium (which damages kidney tubules).
• Importance: In Multiple Myeloma, B2M is one of the most powerful predictors of survival. In kidney health, it can detect “tubular” damage long before standard tests like Creatinine show a problem.

Medical Interpretation

• Crucial Note: B2M is not used to diagnose cancer, but rather to understand how aggressive a known cancer is. Only a specialist can “fine-tune” the interpretation by comparing blood and urine levels to pinpoint the exact site of kidney damage.
• High Blood B2M: May indicate active Multiple Myeloma, Lymphoma, or significantly reduced kidney filtration.
• High Urine B2M: Specifically points to tubular damage or “Tubulointerstitial” kidney disease.

Possible Further Investigations

• Serum Protein Electrophoresis (SPEP): If a plasma cell disorder is suspected.
• Creatinine and GFR: To evaluate overall kidney filtration.
• Bone Marrow Biopsy: To assess the activity of abnormal cells in blood cancers.
• Urinalysis: To look for other signs of kidney strain.
• Consultation with a Hematologist or Nephrologist.

When Does the Next Step Make Sense?

• If B2M is used for cancer monitoring, a rising level often prompts a change in treatment strategy. If used for kidney assessment, high urine B2M may lead to a change in medications (stopping “nephrotoxic” drugs) or further imaging of the kidneys.
• All clinical decisions must be made by a healthcare professional, as B2M must be interpreted in the context of the overall clinical picture.

👉 If necessary, you can discuss the analysis results with a specialist such as a hematologist (Doctors – TAMC) or nephrologist (Doctors – TAMC).